Telisotuzumab Vedotin provides a c-MET-targeting antibody-drug conjugate (ADC) for cancer and oncology research. Also known as ABBV-399, it combines a c-MET-directed monoclonal antibody with monomethyl auristatin E (MMAE) and specifically supports studies of targeted cytotoxicity, non-small cell lung cancer, and antibody-mediated drug delivery.
Key Features and Benefits
- c-MET-Targeting ADC: Combines a c-MET-directed monoclonal antibody with the cytotoxic MMAE payload specifically for targeted cancer research.
- MMAE Payload: Contains monomethyl auristatin E, a potent microtubule-disrupting agent specifically studied in ADC development.
- c-MET Recognition: Supports investigation of c-MET expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Linker: Uses a protease-cleavable valine-citrulline linker specifically to facilitate intracellular MMAE release following cellular uptake.
- Targeted Payload Delivery: Supports investigation of antibody-mediated MMAE delivery to c-MET-expressing cancer cells.
- Microtubule Disruption: MMAE inhibits microtubule polymerization, specifically supporting studies of cell-cycle arrest and ADC-mediated cytotoxicity.
- c-MET-Overexpressing Tumor Research: Supports investigation of ADC activity in cancer models with elevated c-MET protein expression.
- ABBV-399 Research Platform: Provides a well-characterized ADC platform for studying c-MET-directed targeting and payload activity.
Applications
- Non-Small Cell Lung Cancer Research: Supports investigation of c-MET-targeted ADC mechanisms in NSCLC models.
- c-MET-Positive Cancer Research: Useful for studying tumors with elevated c-MET expression and associated targeting mechanisms.
- Lung Adenocarcinoma Research: Supports evaluation of c-MET-directed ADC strategies in relevant lung adenocarcinoma models.
- MET Signaling Research: Useful for investigating c-MET receptor expression, internalization, and related cellular processes.
- ADC Research: Supports studies of antibody targeting, cellular uptake, payload release, and cytotoxic activity.
- Targeted Cancer Research: Useful for investigating antibody-mediated delivery of MMAE to c-MET-expressing cancer cells.
- Cell-Based Cancer Assays: Supports evaluation of c-MET-dependent binding, internalization, and cytotoxic responses.
- Mechanism-of-Action Studies: Supports investigation of c-MET targeting and MMAE-mediated microtubule disruption.
- Comparative ADC Research: Useful for evaluating antibody targets, linker systems, auristatin payloads, and ADC performance.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve antibody and conjugate stability.
Telisotuzumab Vedotin combines c-MET-directed antibody targeting with the microtubule-disrupting MMAE payload and specifically supports non-small cell lung cancer, c-MET-overexpressing tumor, ADC, and targeted drug delivery research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
